首页 > 最新文献

Seminars in Thoracic and Cardiovascular Surgery最新文献

英文 中文
Masthead (Editors) 刊头(编辑)
IF 2.5 3区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.1053/S1043-0679(24)00048-0
{"title":"Masthead (Editors)","authors":"","doi":"10.1053/S1043-0679(24)00048-0","DOIUrl":"https://doi.org/10.1053/S1043-0679(24)00048-0","url":null,"abstract":"","PeriodicalId":48592,"journal":{"name":"Seminars in Thoracic and Cardiovascular Surgery","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141242779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Commentary: How Soon is Now? 评论:现在有多快?
IF 2.5 3区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.1053/j.semtcvs.2023.03.004
Hellmuth R. Muller Moran MD , Rakesh C. Arora MD, PhD, FRCSC
{"title":"Commentary: How Soon is Now?","authors":"Hellmuth R. Muller Moran MD , Rakesh C. Arora MD, PhD, FRCSC","doi":"10.1053/j.semtcvs.2023.03.004","DOIUrl":"10.1053/j.semtcvs.2023.03.004","url":null,"abstract":"","PeriodicalId":48592,"journal":{"name":"Seminars in Thoracic and Cardiovascular Surgery","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9350878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Palliated Hypoplastic Left Heart Syndrome Patients Experience Superior Waitlist and Comparable Post-Heart Transplant Survival to Non-Single Ventricle Congenital Heart Disease Patients 与非单心室先天性心脏病患者相比,缓和型左心室发育不全综合征患者的候诊时间更长,心脏移植后存活率相当。
IF 2.5 3区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.1053/j.semtcvs.2022.08.019
Jason W. Greenberg MD, Muhammad Aanish Raees MBBS, Alia Dani MD, MPH, Haleh C. Heydarian MD, Clifford Chin MD, Farhan Zafar MD, MS, David G. Lehenbauer MD, David L.S. Morales MD

Congenital heart disease (CHD) is a well-established risk factor for inferior waitlist and post-heart transplant survival in children. Differences in outcomes between CHD subgroups are understudied. The present study compared outcomes for palliated hypoplastic left heart syndrome (HLHS) patients to other non-single ventricle CHD (non-SVCHD) and non-CHD patients. United Network for Organ Sharing was used to identify children (age < 18) listed for heart transplant in the United States between 2016 and 2021. CHD sub-diagnoses were only available for United Network for Organ Sharing status 1a after 2015, thereby defining the cohort. Waitlist outcomes were studied using competing-risk time-to-event analysis for transplantation, mortality/decompensation, and alive-on-waitlist. Multivariable Cox proportional hazards regression analyses were used to identify factors associated with inferior post-transplant survival. Patients included: palliated-HLHS (n = 477), non-SVCHD (n = 686), and non-CHD (n = 1261). At listing, Palliated-HLHS patients were older than non-SVCHD (median 2-year [IQR 0-8] vs median 0-year [0-3], respectively) and younger than non-CHD (median 7-year [0-14]) (P < 0.001 vs both), and were more likely to be white (P < 0.01 vs both). Upon time-to-event analysis, rates of waitlist mortality/decompensation rates were greater among non-SVCHD than palliated-HLHS. Post-transplant survival was comparable between palliated-HLHS and non-SVCHD (P = 0.920) but worse compared to non-CHD (P < 0.001). Both palliated-HLHS (HR 2.40 [95% CI 1.68-3.42]) and non-SVSCHD (2.04 [1.39-2.99]) were independently associated with post-transplant mortality. Palliated-HLHS patients with heart failure experience significantly worse post-transplant outcomes than non-CHD but, compared to other CHD patients, experience superior waitlist and comparable post-transplant survival. While a high-risk cohort, HLHS patients can achieve gratifying waitlist and post-transplant survival.

先天性心脏病(CHD)是导致儿童等待心脏移植和移植后存活率较低的一个公认的风险因素。对先天性心脏病亚组之间的预后差异研究不足。本研究将缓和型左心发育不全综合征(HLHS)患者的预后与其他非单室先天性心脏病(non-SVCHD)和非先天性心脏病患者的预后进行了比较。研究使用器官共享联合网络(United Network for Organ Sharing)来识别2016年至2021年期间在美国被列入心脏移植名单的儿童(年龄小于18岁)。只有在 2015 年之后,器官共享联合网络状态 1a 的 CHD 子诊断才可用,从而确定了队列。采用竞争风险时间到事件分析法研究了移植、死亡率/代偿率和候诊存活率的候诊结果。多变量考克斯比例危险回归分析用于确定与移植后存活率较低相关的因素。患者包括:缓和-HLHS(n = 477)、非 SVCHD(n = 686)和非CHD(n = 1261)。入院时,Palliated-HLHS 患者的年龄比非 SVCHD 患者大(中位数分别为 2 年 [IQR 0-8] vs 中位数 0 年 [0-3]),比非CHD 患者年轻(中位数为 7 年 [0-14] )(P < 0.001 vs 两者),更可能是白人(P < 0.01 vs 两者)。从时间到事件的分析来看,非 SVCHD 患者的候诊死亡率/代偿率高于缓和型 HLHS 患者。经姑息治疗的慢性阻塞性肺疾病患者与非慢性阻塞性肺疾病患者的移植后存活率相当(P = 0.920),但与非慢性阻塞性肺疾病患者相比更差(P < 0.001)。姑息-HLHS(HR 2.40 [95% CI 1.68-3.42])和非 SVSCHD(2.04 [1.39-2.99])均与移植后死亡率独立相关。患有心力衰竭的缓和型 HLHS 患者移植后的预后明显差于非心脏病患者,但与其他心脏病患者相比,他们的候选生存率更高,移植后生存率也相当。虽然HLHS患者属于高危人群,但他们在等待移植和移植后的存活率方面都令人满意。
{"title":"Palliated Hypoplastic Left Heart Syndrome Patients Experience Superior Waitlist and Comparable Post-Heart Transplant Survival to Non-Single Ventricle Congenital Heart Disease Patients","authors":"Jason W. Greenberg MD,&nbsp;Muhammad Aanish Raees MBBS,&nbsp;Alia Dani MD, MPH,&nbsp;Haleh C. Heydarian MD,&nbsp;Clifford Chin MD,&nbsp;Farhan Zafar MD, MS,&nbsp;David G. Lehenbauer MD,&nbsp;David L.S. Morales MD","doi":"10.1053/j.semtcvs.2022.08.019","DOIUrl":"10.1053/j.semtcvs.2022.08.019","url":null,"abstract":"<div><p><span><span>Congenital heart disease (CHD) is a well-established risk factor for inferior waitlist and post-heart </span>transplant survival<span><span><span> in children. Differences in outcomes between CHD subgroups are understudied. The present study compared outcomes for palliated hypoplastic left heart syndrome (HLHS) patients to other non-single ventricle CHD (non-SVCHD) and non-CHD patients. United Network for Organ Sharing was used to identify children (age &lt; 18) listed for </span>heart transplant in the United States between 2016 and 2021. CHD sub-diagnoses were only available for United Network for Organ Sharing status 1a after 2015, thereby defining the cohort. Waitlist outcomes were studied using competing-risk time-to-event analysis for transplantation, mortality/decompensation, and alive-on-waitlist. Multivariable Cox </span>proportional hazards regression analyses were used to identify factors associated with inferior post-transplant survival. Patients included: palliated-HLHS (</span></span><em>n =</em> 477), non-SVCHD (<em>n =</em> 686), and non-CHD (<em>n =</em> 1261). At listing, Palliated-HLHS patients were older than non-SVCHD (median 2-year [IQR 0-8] vs median 0-year [0-3], respectively) and younger than non-CHD (median 7-year [0-14]) (<em>P &lt;</em> 0.001 vs both), and were more likely to be white (<em>P &lt;</em> 0.01 vs both). Upon time-to-event analysis, rates of waitlist mortality/decompensation rates were greater among non-SVCHD than palliated-HLHS. Post-transplant survival was comparable between palliated-HLHS and non-SVCHD (<em>P =</em> 0.920) but worse compared to non-CHD (<em>P &lt;</em> 0.001). Both palliated-HLHS (HR 2.40 [95% CI 1.68-3.42]) and non-SVSCHD (2.04 [1.39-2.99]) were independently associated with post-transplant mortality. Palliated-HLHS patients with heart failure experience significantly worse post-transplant outcomes than non-CHD but, compared to other CHD patients, experience superior waitlist and comparable post-transplant survival. While a high-risk cohort, HLHS patients can achieve gratifying waitlist and post-transplant survival.</p></div>","PeriodicalId":48592,"journal":{"name":"Seminars in Thoracic and Cardiovascular Surgery","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9536420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identifying Patients Vulnerable to Inadequate Pain Resolution After Cardiac Surgery 识别心脏手术后容易出现疼痛缓解不充分的患者。
IF 2.5 3区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.1053/j.semtcvs.2022.08.010
Ian Kelly BS , Kara Fields MS , Pankaj Sarin MD , Amanda Pang BS , Martin I. Sigurdsson MD, PhD , Stanton K. Shernan MD , Amanda A. Fox MD, MPH , Simon C. Body MBChB, MPH , Jochen D. Muehlschlegel MD, MMSc, MBA

Acute postoperative pain (APOP) is often evaluated through granular parameters, though monitoring postoperative pain using trends may better describe pain state. We investigated acute postoperative pain trajectories in cardiac surgical patients to identify subpopulations of pain resolution and elucidate predictors of problematic pain courses. We examined retrospective data from 2810 cardiac surgical patients at a single center. The k-means algorithm for longitudinal data was used to generate clusters of pain trajectories over the first 5 postoperative days. Patient characteristics were examined for association with cluster membership using ordinal and multinomial logistic regression. We identified 3 subgroups of pain resolution after cardiac surgery: 37.7% with good resolution, 44.2% with moderate resolution, and 18.2% exhibiting poor resolution. Type I diabetes (2.04 [1.00–4.16], p = 0.05), preoperative opioid use (1.65 [1.23–2.22], p = 0.001), and illicit drug use (1.89 [1.26–2.83], p = 0.002) elevated risk of membership into worse pain trajectory clusters. Female gender (1.72 [1.30–2.27], p < 0.001), depression (1.60 [1.03–2.50], p = 0.04) and chronic pain (3.28 [1.79–5.99], p < 0.001) increased risk of membership in the worst pain resolution cluster. This study defined 3 APOP resolution subgroups based on pain score trend after cardiac surgery and identified factors that predisposed patients to worse resolution. Patients with moderate or poor pain trajectory consumed more opioids and received them for longer before discharge. Future studies are warranted to determine if altering postoperative pain monitoring and management improve postoperative course of patients at risk of moderate or poor pain resolution.

急性术后疼痛(APOP)通常通过颗粒参数进行评估,但利用趋势监测术后疼痛可能会更好地描述疼痛状态。我们研究了心脏外科患者术后急性疼痛的轨迹,以确定疼痛缓解的亚群,并阐明有问题的疼痛过程的预测因素。我们研究了一个中心 2810 名心脏手术患者的回顾性数据。采用纵向数据 k-means 算法生成术后前 5 天的疼痛轨迹群组。使用序数和多项式逻辑回归检验了患者特征与群组成员的关系。我们确定了心脏手术后疼痛缓解的 3 个亚组:37.7%的患者疼痛缓解情况良好,44.2%的患者疼痛缓解情况中等,18.2%的患者疼痛缓解情况较差。I型糖尿病(2.04 [1.00-4.16],p = 0.05)、术前阿片类药物使用(1.65 [1.23-2.22],p = 0.001)和非法药物使用(1.89 [1.26-2.83],p = 0.002)增加了加入较差疼痛轨迹群组的风险。女性(1.72 [1.30-2.27],p < 0.001)、抑郁(1.60 [1.03-2.50],p = 0.04)和慢性疼痛(3.28 [1.79-5.99],p < 0.001)增加了加入最差疼痛解决群组的风险。本研究根据心脏手术后疼痛评分趋势定义了 3 个 APOP 疼痛缓解亚组,并确定了导致患者疼痛缓解更差的易感因素。中度或较差疼痛轨迹的患者在出院前消耗了更多的阿片类药物,接受治疗的时间也更长。今后有必要开展研究,以确定改变术后疼痛监测和管理是否能改善有中度或严重疼痛缓解风险的患者的术后情况。
{"title":"Identifying Patients Vulnerable to Inadequate Pain Resolution After Cardiac Surgery","authors":"Ian Kelly BS ,&nbsp;Kara Fields MS ,&nbsp;Pankaj Sarin MD ,&nbsp;Amanda Pang BS ,&nbsp;Martin I. Sigurdsson MD, PhD ,&nbsp;Stanton K. Shernan MD ,&nbsp;Amanda A. Fox MD, MPH ,&nbsp;Simon C. Body MBChB, MPH ,&nbsp;Jochen D. Muehlschlegel MD, MMSc, MBA","doi":"10.1053/j.semtcvs.2022.08.010","DOIUrl":"10.1053/j.semtcvs.2022.08.010","url":null,"abstract":"<div><p><span><span>Acute postoperative pain<span> (APOP) is often evaluated through granular parameters, though monitoring postoperative pain using trends may better describe pain state. We investigated acute postoperative pain trajectories in cardiac surgical patients to identify subpopulations of pain resolution and elucidate predictors of problematic pain courses. We examined retrospective data from 2810 cardiac surgical patients at a single center. The k-means algorithm for longitudinal data was used to generate clusters of pain trajectories over the first 5 postoperative days. Patient characteristics were examined for association with cluster membership using ordinal and multinomial </span></span>logistic regression<span>. We identified 3 subgroups of pain resolution after cardiac surgery: 37.7% with good resolution, 44.2% with moderate resolution, and 18.2% exhibiting poor resolution. Type I diabetes (2.04 [1.00–4.16], </span></span><em>p</em> = 0.05), preoperative opioid use (1.65 [1.23–2.22], <em>p</em><span> = 0.001), and illicit drug use (1.89 [1.26–2.83], </span><em>p</em> = 0.002) elevated risk of membership into worse pain trajectory clusters. Female gender (1.72 [1.30–2.27], <em>p</em> &lt; 0.001), depression (1.60 [1.03–2.50], <em>p</em> = 0.04) and chronic pain (3.28 [1.79–5.99], <em>p</em> &lt; 0.001) increased risk of membership in the worst pain resolution cluster. This study defined 3 APOP resolution subgroups based on pain score trend after cardiac surgery and identified factors that predisposed patients to worse resolution. Patients with moderate or poor pain trajectory consumed more opioids and received them for longer before discharge. Future studies are warranted to determine if altering postoperative pain monitoring and management improve postoperative course of patients at risk of moderate or poor pain resolution.</p></div>","PeriodicalId":48592,"journal":{"name":"Seminars in Thoracic and Cardiovascular Surgery","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33456399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identifying Actionable Targets to Improve Patient Satisfaction After Cardiac Surgery 确定可行目标,提高心脏手术后患者的满意度。
IF 2.5 3区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.1053/j.semtcvs.2022.09.005
Ko Bando MD, PhD
{"title":"Identifying Actionable Targets to Improve Patient Satisfaction After Cardiac Surgery","authors":"Ko Bando MD, PhD","doi":"10.1053/j.semtcvs.2022.09.005","DOIUrl":"10.1053/j.semtcvs.2022.09.005","url":null,"abstract":"","PeriodicalId":48592,"journal":{"name":"Seminars in Thoracic and Cardiovascular Surgery","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40376124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AATS 2021 Virtual Annual Meeting AATS 2021 虚拟年会。
IF 2.5 3区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.1053/j.semtcvs.2022.09.014
{"title":"AATS 2021 Virtual Annual Meeting","authors":"","doi":"10.1053/j.semtcvs.2022.09.014","DOIUrl":"10.1053/j.semtcvs.2022.09.014","url":null,"abstract":"","PeriodicalId":48592,"journal":{"name":"Seminars in Thoracic and Cardiovascular Surgery","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141180826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Force Profiles of Single Ventricle Atrioventricular Leaflets in Response to Annular Dilation and Leaflet Tethering 单心室房室小叶在瓣环扩张和小叶系带作用下的力图。
IF 2.5 3区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.1053/j.semtcvs.2022.09.012
Sumanth Kidambi MD , Stephen C. Moye BS , James Lee BA , Teaghan H. Cowles BS , E. Brandon Strong MS , Rob Wilkerson BS , Michael J. Paulsen MD , Y. Joseph Woo MD , Michael R. Ma MD

We sought to understand how leaflet forces change in response to annular dilation and leaflet tethering (LT) in single ventricle physiology. Explanted fetal bovine tricuspid valves were sutured onto image-derived annuli and ventricular mounts. Control valves (CON) were secured to a size-matched hypoplastic left heart syndrome (HLHS)-type annulus and compared to: (1) normal tricuspid valves secured to a size-matched saddle-shaped annulus, (2) HLHS-type annulus with LT, (3) HLHS-type annulus with annular dilation (dilation valves), or (4) a combined disease model with both dilation and tethering (disease valves). The specimens were tested in a systemic heart simulator at various single ventricle physiologies. Leaflet forces were measured using optical strain sensors sutured to each leaflet edge. Average force in the anterior leaflet was 43.2% lower in CON compared to normal tricuspid valves (P < 0.001). LT resulted in a 6.6% increase in average forces on the anterior leaflet (P = 0.04), 10.7% increase on the posterior leaflet (P = 0.03), and 14.1% increase on the septal leaflet (P < 0.001). In dilation valves, average septal leaflet forces increased relative to the CON by 42.2% (P = 0.01). In disease valves, average leaflet forces increased by 54.8% in the anterior leaflet (P < 0.001), 37.6% in the posterior leaflet (P = 0.03), and 79.9% in the septal leaflet (P < 0.001). The anterior leaflet experiences the highest forces in the normal tricuspid annulus under single ventricle physiology conditions. Annular dilation resulted in an increase in forces on the septal leaflet and LT resulted in an increase in forces across all 3 leaflets. Annular dilation and LT combined resulted in the largest increase in leaflet forces across all 3 leaflets.

我们试图了解在单心室生理学中,瓣叶力是如何随着瓣环扩张和瓣叶系带(LT)而变化的。将取出的胎牛三尖瓣缝合到图像衍生的瓣环和心室支架上。将对照瓣膜(CON)固定在大小匹配的发育不全左心综合征(HLHS)型瓣环上,并与下列瓣膜进行比较:(1)固定在大小匹配的鞍形环上的正常三尖瓣,(2)带有LT的HLHS型环,(3)带有环扩张的HLHS型环(扩张瓣),或(4)带有扩张和系带的综合疾病模型(疾病瓣)。试样在系统心脏模拟器中进行了各种单心室生理状态下的测试。使用缝合在每个瓣叶边缘的光学应变传感器测量瓣叶力。与正常三尖瓣相比,CON 三尖瓣前叶的平均受力降低了 43.2%(P < 0.001)。LT导致前叶平均力增加6.6%(P = 0.04),后叶增加10.7%(P = 0.03),隔叶增加14.1%(P < 0.001)。在扩张瓣中,隔叶的平均作用力相对于CON增加了42.2%(P = 0.01)。在疾病瓣膜中,前叶的平均瓣叶力增加了 54.8%(P < 0.001),后叶增加了 37.6%(P = 0.03),隔叶增加了 79.9%(P < 0.001)。在单心室生理条件下,正常三尖瓣瓣环中前叶承受的力最大。瓣环扩张导致室间隔瓣叶受力增加,而LT导致所有3片瓣叶受力增加。瓣环扩张和LT结合导致所有3片瓣叶受力的最大增加。
{"title":"Force Profiles of Single Ventricle Atrioventricular Leaflets in Response to Annular Dilation and Leaflet Tethering","authors":"Sumanth Kidambi MD ,&nbsp;Stephen C. Moye BS ,&nbsp;James Lee BA ,&nbsp;Teaghan H. Cowles BS ,&nbsp;E. Brandon Strong MS ,&nbsp;Rob Wilkerson BS ,&nbsp;Michael J. Paulsen MD ,&nbsp;Y. Joseph Woo MD ,&nbsp;Michael R. Ma MD","doi":"10.1053/j.semtcvs.2022.09.012","DOIUrl":"10.1053/j.semtcvs.2022.09.012","url":null,"abstract":"<div><p><span>We sought to understand how leaflet forces change in response to annular dilation and leaflet tethering (LT) in single ventricle<span> physiology. Explanted fetal bovine tricuspid valves<span> were sutured onto image-derived annuli and ventricular mounts. Control valves (CON) were secured to a size-matched hypoplastic left heart syndrome (HLHS)-type annulus and compared to: (1) normal tricuspid valves secured to a size-matched saddle-shaped annulus, (2) HLHS-type annulus with LT, (3) HLHS-type annulus with annular dilation (dilation valves), or (4) a combined disease model with both dilation and tethering (disease valves). The specimens were tested in a systemic heart simulator at various single ventricle physiologies. Leaflet forces were measured using optical strain sensors sutured to each leaflet edge. Average force in the anterior leaflet was 43.2% lower in CON compared to normal tricuspid valves (</span></span></span><em>P &lt;</em> 0.001). LT resulted in a 6.6% increase in average forces on the anterior leaflet (<em>P =</em> 0.04), 10.7% increase on the posterior leaflet (<em>P =</em> 0.03), and 14.1% increase on the septal leaflet (<em>P &lt;</em> 0.001). In dilation valves, average septal leaflet forces increased relative to the CON by 42.2% (<em>P =</em> 0.01). In disease valves, average leaflet forces increased by 54.8% in the anterior leaflet (<em>P &lt;</em> 0.001), 37.6% in the posterior leaflet (<em>P =</em> 0.03), and 79.9% in the septal leaflet (<em>P &lt;</em> 0.001). The anterior leaflet experiences the highest forces in the normal tricuspid annulus under single ventricle physiology conditions. Annular dilation resulted in an increase in forces on the septal leaflet and LT resulted in an increase in forces across all 3 leaflets. Annular dilation and LT combined resulted in the largest increase in leaflet forces across all 3 leaflets.</p></div>","PeriodicalId":48592,"journal":{"name":"Seminars in Thoracic and Cardiovascular Surgery","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9536422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgical Outcomes After Reconstruction of the Aortomitral Curtain 重建主动脉瓣幕后的手术效果
IF 2.5 3区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.1053/j.semtcvs.2022.11.008
Markian Bojko MD, MPH , Korri S. Hershenhouse MD , Ramsey S. Elsayed MD , Brittany Abt MD , Robbin G. Cohen MD. MMM , Raymond Lee MD , Michael E. Bowdish MD, MS , Vaughn A. Starnes MD

Repair of concomitant aortic and mitral valvular disease with involvement of the aortomitral curtain requires a technically complex operation colloquially termed the commando procedure. Surgical outcomes of this procedure are not well described. The objective of this study was to examine outcomes of the commando procedure at our center. We identified all patients undergoing concomitant aortic and mitral valve replacements from 2004–2021. Of 363 patients, 41 underwent reconstruction of the aortomitral curtain. Survival analysis and multivariable modeling were used to examine outcomes and risk factors for mortality. The median age was 52 (IQR 44-71) years. Preoperatively, 4 of 41 (9.8%) patients had renal failure, and 10 of 41 (24.4%) had a stroke. The most common surgical indication was endocarditis in 25 of 41 (61.0%) patients. 25 of 41 (61.0%) patients underwent redo sternotomy, and 23 of 41 (56.1%) had previous prosthetic valves. Operative mortality was 14 of 41 (34.1%), and 8 of 41 (9.5%) patients received a permanent pacemaker. Survival at 1, 3, and 5 years was 55.4% (95% confidence interval (CI), 40.6–75.5%), 50.3% (35.0–72.3%), and 37.7% (19.3–73.9%) respectively. Cox proportional hazards regression identified previous sternotomy (HR 4.76, 95% CI 1.21–18.73), and female gender (HR 1.39, 95% CI 1.17–13.82) as risk factors for mortality. Patients undergoing reconstruction of the aortomitral curtain represent a high-risk population with complex surgical indications. Due to high perioperative morbidity and mortality, this procedure should be performed only when necessary. Despite a high up front morbidity burden, outcomes remain favorable for patients who survive the initial hospitalization.

同时患有主动脉瓣和二尖瓣疾病并累及主动脉-二尖瓣瓣膜时,需要进行技术复杂的修复手术,俗称 "突击队手术"。关于这种手术的结果还没有很好的描述。本研究的目的是检查我们中心的突击队手术效果。我们确定了 2004-2021 年间所有同时接受主动脉瓣和二尖瓣置换术的患者。在363名患者中,有41人接受了主动脉瓣帘重建术。研究人员采用生存分析和多变量模型来检验结果和死亡风险因素。中位年龄为 52(IQR 44-71)岁。术前,41 位患者中有 4 位(9.8%)出现肾功能衰竭,41 位患者中有 10 位(24.4%)出现中风。41 位患者中有 25 位(61.0%)最常见的手术指征是心内膜炎。41名患者中有25名(61.0%)接受了再次胸骨切开术,41名患者中有23名(56.1%)曾接受过人工瓣膜手术。手术死亡率为41例中的14例(34.1%),41例患者中有8例(9.5%)接受了永久起搏器治疗。1年、3年和5年的存活率分别为55.4%(95%置信区间,40.6-75.5%)、50.3%(35.0-72.3%)和37.7%(19.3-73.9%)。Cox比例危险回归确定既往胸骨切开术(HR 4.76,95% CI 1.21-18.73)和女性性别(HR 1.39,95% CI 1.17-13.82)为死亡率的风险因素。接受主动脉瓣帘重建手术的患者属于高危人群,手术适应症复杂。由于围手术期的发病率和死亡率较高,只有在必要时才能进行该手术。尽管前期发病率较高,但对于在最初住院期间存活下来的患者来说,治疗效果仍然很好。
{"title":"Surgical Outcomes After Reconstruction of the Aortomitral Curtain","authors":"Markian Bojko MD, MPH ,&nbsp;Korri S. Hershenhouse MD ,&nbsp;Ramsey S. Elsayed MD ,&nbsp;Brittany Abt MD ,&nbsp;Robbin G. Cohen MD. MMM ,&nbsp;Raymond Lee MD ,&nbsp;Michael E. Bowdish MD, MS ,&nbsp;Vaughn A. Starnes MD","doi":"10.1053/j.semtcvs.2022.11.008","DOIUrl":"10.1053/j.semtcvs.2022.11.008","url":null,"abstract":"<div><p><span><span>Repair of concomitant aortic and mitral valvular disease with involvement of the aortomitral curtain requires a technically complex operation colloquially termed the commando procedure. Surgical outcomes of this procedure are not well described. The objective of this study was to examine outcomes of the commando procedure at our center. We identified all patients undergoing concomitant aortic and </span>mitral valve replacements<span> from 2004–2021. Of 363 patients, 41 underwent reconstruction of the aortomitral curtain. Survival analysis and multivariable modeling were used to examine outcomes and risk factors for mortality. The median age was 52 (IQR 44-71) years. Preoperatively, 4 of 41 (9.8%) patients had renal failure, and 10 of 41 (24.4%) had a stroke. The most common surgical indication was endocarditis in 25 of 41 (61.0%) patients. 25 of 41 (61.0%) patients underwent redo </span></span>sternotomy<span><span>, and 23 of 41 (56.1%) had previous prosthetic valves<span><span>. Operative mortality was 14 of 41 (34.1%), and 8 of 41 (9.5%) patients received a </span>permanent pacemaker. Survival at 1, 3, and 5 years was 55.4% (95% confidence interval (CI), 40.6–75.5%), 50.3% (35.0–72.3%), and 37.7% (19.3–73.9%) respectively. Cox </span></span>proportional hazards regression identified previous sternotomy (HR 4.76, 95% CI 1.21–18.73), and female gender (HR 1.39, 95% CI 1.17–13.82) as risk factors for mortality. Patients undergoing reconstruction of the aortomitral curtain represent a high-risk population with complex surgical indications. Due to high perioperative morbidity and mortality, this procedure should be performed only when necessary. Despite a high up front morbidity burden, outcomes remain favorable for patients who survive the initial hospitalization.</span></p></div>","PeriodicalId":48592,"journal":{"name":"Seminars in Thoracic and Cardiovascular Surgery","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10732712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Benefit of adjuvant chemotherapy for resected pathologic N1 non-small cell lung cancer is unrecognized: A subgroup analysis of the JBR10 trial 辅助化疗对切除的病理性 N1 非小细胞肺癌的益处尚未得到认可:JBR10试验的亚组分析。
IF 2.5 3区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.1053/j.semtcvs.2022.10.005
Omar Toubat PhD , Li Ding MD, MPH , Keyue Ding PhD , Sean C. Wightman MD , Scott M. Atay MD , Takashi Harano MD , Anthony W. Kim MD , Elizabeth A. David MD, MAS

Adjuvant chemotherapy is underutilized in clinical practice, in part, because its anticipated survival benefit is limited. We evaluated the impact of AC on overall and recurrence-free survival among completely resected pN1 NSCLC patients enrolled in the North American Intergroup phase III (JBR10) trial. A post-hoc subgroup analysis of pN1 NSCLC patients was performed. Participants were randomized to cisplatin+vinorelbine (AC) (n = 118) or observation (n = 116) following complete resection. The primary endpoint was overall survival (OS). The secondary endpoint was recurrence free survival (RFS). Kaplan-Meier methods were used to compare OS and RFS between the two treatment groups. Cox regression was used to identify factors associated with OS and RFS endpoints. Both groups had similar baseline characteristics. AC patients had improved 5-year OS (AC 61.4% vs observation 41.0%, log-rank p = .008) and 5-year RFS (AC 56.2% vs observation 39.9%, log-rank p = .011) rates compared to observation. Cox regression analyses confirmed the OS (HR 0.583, 95% CI 0.402-0.846, p = .005) and RFS (HR 0.573, 95% CI 0.395-0.830, p = .003) benefit associated with AC. AC was associated with a lower risk (HR 0.648, 95% CI 0.435-0.965, p = .0326) and a lower cumulative incidence (Subdistribution Hazard Ratio [SHR], 0.67, 95% CI 0.449-0.999, p = .0498) of lung cancer deaths. In the JBR10 trial, treatment with AC conferred a significant OS and RFS advantage over observation for pN1 NSCLC patients. These data suggest that pN1 NSCLC patients may experience a disproportionately greater clinical benefit from AC than the 6% survival advantage estimated by the LACE meta-analysis.

辅助化疗在临床实践中未得到充分利用,部分原因是其预期的生存获益有限。我们评估了在参加北美组间 III 期(JBR10)试验的完全切除 pN1 NSCLC 患者中,辅助化疗对总生存期和无复发生存期的影响。对 pN1 NSCLC 患者进行了事后亚组分析。参与者在完全切除术后随机接受顺铂+维诺瑞宾(AC)治疗(n = 118)或观察治疗(n = 116)。主要终点是总生存期(OS)。次要终点是无复发生存期(RFS)。采用 Kaplan-Meier 方法比较两个治疗组的 OS 和 RFS。Cox回归用于确定与OS和RFS终点相关的因素。两组患者的基线特征相似。与观察组相比,AC 患者的 5 年 OS(AC 61.4% vs 观察组 41.0%,log-rank p = .008)和 5 年 RFS(AC 56.2% vs 观察组 39.9%,log-rank p = .011)率均有所提高。Cox 回归分析证实了 AC 带来的 OS(HR 0.583,95% CI 0.402-0.846,p = .005)和 RFS(HR 0.573,95% CI 0.395-0.830,p = .003)益处。AC 与较低的肺癌死亡风险(HR 0.648,95% CI 0.435-0.965,p = .0326)和较低的累积发病率(子分布危险比 [SHR],0.67,95% CI 0.449-0.999,p = .0498)相关。在JBR10试验中,对于pN1 NSCLC患者,AC治疗比观察治疗具有显著的OS和RFS优势。这些数据表明,与 LACE 荟萃分析估计的 6% 生存率优势相比,pN1 NSCLC 患者从 AC 治疗中获得的临床获益可能更大。
{"title":"Benefit of adjuvant chemotherapy for resected pathologic N1 non-small cell lung cancer is unrecognized: A subgroup analysis of the JBR10 trial","authors":"Omar Toubat PhD ,&nbsp;Li Ding MD, MPH ,&nbsp;Keyue Ding PhD ,&nbsp;Sean C. Wightman MD ,&nbsp;Scott M. Atay MD ,&nbsp;Takashi Harano MD ,&nbsp;Anthony W. Kim MD ,&nbsp;Elizabeth A. David MD, MAS","doi":"10.1053/j.semtcvs.2022.10.005","DOIUrl":"10.1053/j.semtcvs.2022.10.005","url":null,"abstract":"<div><p><span>Adjuvant chemotherapy is underutilized in clinical practice, in part, because its anticipated survival benefit is limited. We evaluated the impact of AC on overall and recurrence-free survival among completely resected pN1 </span>NSCLC<span><span><span> patients enrolled in the North American Intergroup phase III (JBR10) trial. A post-hoc subgroup analysis of pN1 NSCLC patients was performed. Participants were randomized to cisplatin+vinorelbine (AC) (n = 118) or observation (n = 116) following complete resection. The primary endpoint was overall survival (OS). The secondary endpoint was recurrence free survival (RFS). Kaplan-Meier methods were used to compare OS and RFS between the two </span>treatment groups. </span>Cox regression was used to identify factors associated with OS and RFS endpoints. Both groups had similar baseline characteristics. AC patients had improved 5-year OS (AC 61.4% vs observation 41.0%, log-rank p = .008) and 5-year RFS (AC 56.2% vs observation 39.9%, log-rank p = .011) rates compared to observation. Cox regression analyses confirmed the OS (HR 0.583, 95% CI 0.402-0.846, p = .005) and RFS (HR 0.573, 95% CI 0.395-0.830, p = .003) benefit associated with AC. AC was associated with a lower risk (HR 0.648, 95% CI 0.435-0.965, p = .0326) and a lower cumulative incidence (Subdistribution Hazard Ratio [SHR], 0.67, 95% CI 0.449-0.999, p = .0498) of lung cancer deaths. In the JBR10 trial, treatment with AC conferred a significant OS and RFS advantage over observation for pN1 NSCLC patients. These data suggest that pN1 NSCLC patients may experience a disproportionately greater clinical benefit from AC than the 6% survival advantage estimated by the LACE meta-analysis.</span></p></div>","PeriodicalId":48592,"journal":{"name":"Seminars in Thoracic and Cardiovascular Surgery","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40673677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Staged Ventricular Septation in Double-Inlet Ventricle - A Strategy to Avoid Fontan? 双入口心室的分期室间隔缺损--避免 Fontan 的策略?
IF 2.5 3区 医学 Q1 Medicine Pub Date : 2024-03-01 DOI: 10.1053/j.semtcvs.2022.08.014
Anagha Prasanna AB , Rebecca S. Beroukhim MD , Sunil Ghelani MD , Eric N. Feins MD , Pedro J. del Nido MD , Sitaram M. Emani MD

Single-stage ventricular septation for double-inlet left or right ventricle (DILV or DIRV) has historically been associated with poor outcomes. We hypothesize that staged ventricular septation may demonstrate favorable clinical outcomes to be an alternative to Fontan palliation. This single-center retrospective study reviewed patients with DILV or DIRV who underwent staged ventricular septation between 2015–2021. The strategy involves pulmonary artery banding or Norwood procedure during infancy (stage 1), followed by partial ventricular septation to anchor the septum, while maintaining systemic RV pressure to avoid septal shift (stage 2). Residual septal defects are closed with pulmonary artery band removal at stage 3. Results are reported as median (interquartile range). Twelve patients underwent partial ventricular septation. At a median follow-up time of 17 months (8–30) after stage 2, there were no interstage deaths or cardiac transplants; LV dysfunction was observed in one patient. Hemodynamic evaluation after stage 2 demonstrated median left atrial pressure of 9.5 mm Hg (8.9–11.5), cardiac index of 3.4 L/min/m2 (3.2–3.6), and RV and LV indexed end-diastolic volumes of 52 ml/m2 (41–67) and 105 ml/m2 (81–115), respectively. Five patients have progressed to stage 3; one required pacemaker for complete heart block. Unplanned reintervention was required in 4 patients after stage 1, 2 patients after stage 2, and 3 patients after stage 3. Staged ventricular septation is an alternative to single-ventricle palliation in a subset of double-inlet ventricle patients and is associated with acceptable early outcomes. Further studies are necessary to determine long-term outcomes.

左心室或右心室双入口(DILV 或 DIRV)的单期室间隔置换术历来疗效不佳。我们假设,分期室间隔术可能会显示出良好的临床疗效,成为丰坦姑息术的替代方案。这项单中心回顾性研究回顾了2015-2021年间接受分期室间隔术的DILV或DIRV患者。该策略包括在婴儿期进行肺动脉束带术或诺伍德手术(第一阶段),然后进行部分室间隔成形术以固定室间隔,同时维持系统性 RV 压力以避免室间隔移位(第二阶段)。在第三阶段切除肺动脉束带,关闭残余的房间隔缺损。结果以中位数(四分位数间距)报告。12名患者接受了部分室间隔成形术。第 2 阶段后的中位随访时间为 17 个月(8-30 个月),没有发生阶段间死亡或心脏移植;一名患者出现左心室功能障碍。第 2 期后的血液动力学评估显示,中位左心房压为 9.5 mm Hg(8.9-11.5),心脏指数为 3.4 L/min/m2 (3.2-3.6),RV 和 LV 指数舒张末期容积分别为 52 ml/m2 (41-67)和 105 ml/m2 (81-115)。五名患者的病情已发展到第三阶段,其中一名患者因完全性心脏传导阻滞而需要安装起搏器。4 名患者在 1 期、2 名患者在 2 期、3 名患者在 3 期后需要进行计划外的再介入治疗。对于部分双入口心室患者来说,分期室间隔术是单心室姑息术的替代方案,其早期疗效可以接受。要确定长期疗效,还需要进一步研究。
{"title":"Staged Ventricular Septation in Double-Inlet Ventricle - A Strategy to Avoid Fontan?","authors":"Anagha Prasanna AB ,&nbsp;Rebecca S. Beroukhim MD ,&nbsp;Sunil Ghelani MD ,&nbsp;Eric N. Feins MD ,&nbsp;Pedro J. del Nido MD ,&nbsp;Sitaram M. Emani MD","doi":"10.1053/j.semtcvs.2022.08.014","DOIUrl":"10.1053/j.semtcvs.2022.08.014","url":null,"abstract":"<div><p><span><span><span>Single-stage ventricular septation for double-inlet left or right ventricle<span><span> (DILV or DIRV) has historically been associated with poor outcomes. We hypothesize that staged ventricular septation may demonstrate favorable clinical outcomes to be an alternative to Fontan palliation. This single-center retrospective study reviewed patients with DILV or DIRV who underwent staged ventricular septation between 2015–2021. The strategy involves </span>pulmonary artery banding or </span></span>Norwood procedure<span><span> during infancy (stage 1), followed by partial ventricular septation to anchor the septum, while maintaining systemic RV pressure to avoid septal shift (stage 2). Residual septal defects are closed with pulmonary artery band removal at stage 3. Results are reported as median (interquartile range). Twelve patients underwent partial ventricular septation. At a median follow-up time of 17 months (8–30) after stage 2, there were no interstage deaths or cardiac transplants; LV dysfunction was observed in one patient. </span>Hemodynamic evaluation after stage 2 demonstrated median </span></span>left atrial pressure of 9.5 mm Hg (8.9–11.5), cardiac index of 3.4 L/min/m</span><sup>2</sup> (3.2–3.6), and RV and LV indexed end-diastolic volumes of 52 ml/m<sup>2</sup> (41–67) and 105 ml/m<sup>2</sup><span> (81–115), respectively. Five patients have progressed to stage 3; one required pacemaker for complete heart block. Unplanned reintervention was required in 4 patients after stage 1, 2 patients after stage 2, and 3 patients after stage 3. Staged ventricular septation is an alternative to single-ventricle palliation in a subset of double-inlet ventricle patients and is associated with acceptable early outcomes. Further studies are necessary to determine long-term outcomes.</span></p></div>","PeriodicalId":48592,"journal":{"name":"Seminars in Thoracic and Cardiovascular Surgery","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33458871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Seminars in Thoracic and Cardiovascular Surgery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1